Teva Pharmaceutical Industries Assets & Liabilities Overview 2010-2023 | TEVA
Current and historical assets & liabilities overview for Teva Pharmaceutical Industries (TEVA) from 2010 to 2023.
Teva Pharmaceutical Industries Annual Assets & Liabilities Overview (Millions of US $) |
Teva Pharmaceutical Industries Quarterly Assets & Liabilities Overview (Millions of US $) |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$14.585B |
$15.846B |
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|